Gene Editing

Global Gene Editing Market to Reach US$18.5 Billion by 2030

The global market for Gene Editing estimated at US$8.1 Billion in the year 2024, is expected to reach US$18.5 Billion by 2030, growing at a CAGR of 14.8% over the analysis period 2024-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$6.9 Billion by the end of the analysis period. Growth in the Zinc Finger Nucleases Technology segment is estimated at 16.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 19.4% CAGR

The Gene Editing market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 19.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Global Gene Editing Market – Key Trends & Drivers Summarized

How Is Gene Editing Transforming Biotechnology and Medicine?

Gene editing has emerged as one of the most revolutionary advancements in biotechnology, enabling precise modifications to an organism`s DNA to correct genetic defects, enhance traits, or combat diseases. Technologies such as CRISPR-Cas9, TALENs (Transcription Activator-Like Effector Nucleases), and ZFNs (Zinc Finger Nucleases) have drastically improved the efficiency and accuracy of genetic modifications, making gene editing more accessible for research, agriculture, and medical applications. This ability to make targeted changes at the DNA level has positioned gene editing at the forefront of personalized medicine, genetic disease therapy, and advanced biopharmaceutical development.

The growing demand for gene therapies and regenerative medicine has accelerated research and investment in gene editing. Diseases such as sickle cell anemia, cystic fibrosis, and certain types of cancers are being targeted for treatment using CRISPR-based therapies, with clinical trials demonstrating promising results. Beyond medicine, gene editing is also reshaping agriculture, allowing for the development of genetically modified crops with improved resistance to pests, drought, and diseases. Additionally, breakthroughs in synthetic biology have enabled researchers to engineer bacteria and yeast strains for sustainable biofuel and pharmaceutical production. As regulatory frameworks evolve and ethical considerations are addressed, gene editing is expected to become a critical tool for advancing health sciences and food security.

Which Industries Are Driving the Demand for Gene Editing Technologies?

The healthcare and pharmaceutical industries are at the forefront of gene editing applications, with increasing investments in gene therapy, precision medicine, and stem cell research. CRISPR-based therapies are being explored for treating rare genetic disorders, infectious diseases, and even age-related conditions. Biopharmaceutical companies are leveraging gene editing to develop next-generation biologics, including engineered T-cell therapies (CAR-T) for cancer treatment. Additionally, advancements in in vivo gene editing have paved the way for potential treatments that directly modify patient DNA without the need for ex vivo manipulation.

In agriculture, gene editing is revolutionizing crop improvement by enabling the precise alteration of plant genomes without introducing foreign DNA, making it distinct from traditional genetically modified organisms (GMOs). This has led to the development of climate-resilient crops with enhanced nutritional profiles, higher yields, and reduced reliance on chemical pesticides. Additionally, livestock breeding programs are incorporating gene editing to enhance disease resistance and improve productivity. The environmental sector is also exploring gene editing for bioremediation applications, such as engineering microorganisms to break down pollutants and reduce greenhouse gas emissions. As gene editing continues to expand its reach, demand across these diverse industries is expected to grow.

What Are the Latest Technological Advancements in Gene Editing?

Recent breakthroughs in gene editing technologies have significantly improved precision, efficiency, and scalability. CRISPR-based advancements, including base editing and prime editing, have enabled scientists to make precise DNA modifications without causing double-stranded breaks, reducing the risk of unintended mutations. These refined techniques are opening new possibilities for correcting genetic disorders at the molecular level with greater safety and accuracy. Additionally, the development of CRISPR-Cas variants with expanded targeting capabilities has broadened the range of editable genomic regions, further enhancing the versatility of gene editing tools.

Beyond CRISPR, synthetic biology and AI-powered gene prediction models are accelerating the discovery of novel gene editing targets. AI-driven algorithms are optimizing guide RNA designs, improving editing efficiency, and predicting potential off-target effects. Moreover, the integration of gene editing with single-cell sequencing technologies has enabled more detailed analysis of genetic modifications, leading to better control over gene expression and cellular behavior. These advancements are driving the next wave of innovation in biotechnology, unlocking new therapeutic opportunities and expanding gene editing applications beyond traditional boundaries.

What Factors Are Fueling the Growth of the Gene Editing Market?

The growth in the gene editing market is driven by several factors, including increasing investments in biotechnology research, rising demand for gene therapies, and technological advancements in genome engineering. Government initiatives and funding for genetic research have expanded, with agencies such as the National Institutes of Health (NIH) and private biotech firms committing substantial resources to gene editing innovation. The accelerating pace of clinical trials for CRISPR-based therapies has further validated the potential of gene editing in personalized medicine, prompting regulatory agencies to refine approval pathways for genetic interventions.

Additionally, the agriculture sector’s growing need for sustainable and resilient crops has boosted the adoption of gene editing technologies. As global food security concerns rise, precision breeding methods enabled by CRISPR and other gene editing tools are becoming increasingly important. The emergence of AI-driven gene editing platforms, enhanced bioinformatics tools, and machine learning applications has also contributed to market expansion by optimizing editing accuracy and efficiency. As ethical guidelines evolve and regulatory approvals streamline, gene editing is expected to become a key driver of scientific and medical advancements, shaping the future of healthcare, agriculture, and environmental sustainability.

SCOPE OF STUDY:

The report analyzes the Gene Editing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (CRISPR / CAS9 Technology, Zinc Finger Nucleases Technology, Talens Technology, Other Technologies); Application (Cell Line Engineering Application, Animal Genetic Engineering Application, Plant Genetic Engineering Application, Other Applications); End-User (Biotech & Pharma Companies End-User, Contract Research Organizations End-User, Research Institutes End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Arcturus Therapeutics
• Beam Therapeutics
• Caribou Biosciences
• Century Therapeutics
• CRISPR Therapeutics
• Editas Medicine
• Horizon Discovery Limited
• Inscripta
• Integrated DNA Technologies
• Intellia Therapeutics
• Life Edit Therapeutics
• Metagenomi
• New England Biolabs
• OriGene Technologies
• Precision BioSciences
• Prime Medicine
• Regeneron Pharmaceuticals
• Sangamo Therapeutics
• Synthego
• Ubigene Biosciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.